Abstract  Despite the high cure rates achieved with intensified primary therapies for childhood non-Hodgkin’s lymphomas (NHL), the prognosis
for children with relapsed or refractory disease is poor. Optimal treatment for this group remains a challenge. Dose intensification
followed by stem cell transplantation has been used in these circumstances and may provide a curative treatment option for
these patients, but the number of children treated using this approach is relatively small and its effectiveness has been
difficult to judge. Moreover, the limited experience is insufficient to define the patient most likely to benefit from transplantation.
Likewise, the selection of autologous or allogeneic transplantation and the optimal conditioning regimen are debated. We summari…

Iverson Genetic Diagnostics announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded …

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings (LabCorp) for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus (HCV) infection to peginterferon alpha-based therapy.

Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and …

Nicotinic acetylcholine receptor α1 promotes calpain-1 activation and macrophage inflammation in hypercholesterolemic nephropathy

Laboratory Investigation advance online publication, July 26, 2010. doi:10.1038/labinvest.2010.135

Authors: Guoqiang Zhang, Alison L Thomas, Amanda L Marshall, Kelly A Kernan, Yanyuan Su, Yi Zheng, Jiro Takano, Takaomi C Saido
& Allison A Eddy (Source: Laboratory Investigation AOP)

Merck today announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

Calibra Medical announced today it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk’s Novolog® rapid acting insulin. Combining the mealtime therapy-adherence benefits of insulin pumps with the simplicity and affordability of syringes and pens, Calibra’s novel bolus-only patch-pen is a …

Most men who are diagnosed with prostate cancer appear to under undergo aggressive therapy, even if they have a low prostate-specific antigen (PSA) level and low-risk disease, according to a report in the July 26 issue of Archives of Internal Medicine.

A Spanish man who underwent the world’s first full face transplant appeared before TV cameras Monday for the first time since his surgery, thanking his doctors and the family of the donor.

QRxPharmareported today positive outcomes of its European Scientific Advice meetings on the development and registration of MoxDuo IR, an immediate release Dual-Opioid™ pain therapy. The Company is currently completing pivotal Phase 3 trials required for filing a New Drug Application (NDA) for MoxDuo IR with the United States Food and Drug Administration (FDA).

Brainlab announced the availability of ExacTrac® Infrared Monitoring, an add-on device to existing treatment machines for monitoring patient positioning during radiation therapy treatments, at the American Association of Physicists in Medicine (AAPM) Annual Meeting last week.

ATLANTA—-Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy.

A novel in vivo genetic screen for Hepatitis C virus (HCV) Protease Inhibitors has been developed based on the concerted co-expression of a reporter gene, recombinant Hepatitis C virus (HCV) non-structural 3 (NS3) protease and a potential inhibitor…

Oscar (right), a man who underwent a full-face transplant in April, poses with the Spanish Dr. Joan Barret for the photographers as he appears in public for the first time in a news conference in Barcelona, Spain, Monday, July 26, 2010. (AP) MADRID (AP) – A Spanish man who underwent the world’s first full face transplant appeared before TV cameras Monday for the first time since his surgery …

First full face transplant for Spanish man who accidentally shot himself five years ago.

More than 75% of men diagnosed with low-risk prostate cancer undergo aggressive treatment — either complete removal of the prostate or radiation therapy, according to a new study.

Human Gene Therapy , Vol. 0, No. 0. (Source: Human Gene Therapy)

Human Gene Therapy , Vol. 0, No. 0. (Source: Human Gene Therapy)

The objective of this investigation was to determine if simultaneous silencing of the human papillomavirus type 18 (HPV-18) E6 and E7 oncogenes using RNA interference (RNAi) would be a potential therapeutic approach against the carcinogenic activity of this virus. Two synthetic double-stranded oligonucleotides, encoding short hairpin transcripts corresponding to HPV-18 E6 and E7 genes, were cloned into pGenesilence (pGS) 1.0 vectors to produce pGS-E6, pGS-E7, and pGS-(E6+E7), respectively. Our results showed that the expression of HPV-18 E6 class 1 and HPV-18 E7 in HeLa cells was markedly decreased after being transfected with pGS-E6, pGS-E7, and pGS-(E6+E7) vectors. Of the three vectors, pGS-(E6+E7) had a greater ability to decrease the growth rate of HeLa cells, inhibit colony formation …

A genetic clue uncovered by scientists enables doctors to predict, for the first time, which children with T-cell acute lymphoblastic leukemia (T-ALL) are unlikely to benefit from standard chemotherapy for the disease and should therefore be among the first to receive new treatments in future clinical trials.